Claris GenomiX, Inc. Information

Claris GenomiX is transforming precision oncology by innovating a suite of mRNA-based molecular diagnostic tests that show promise in significantly improving the lives of cancer patients in 15 solid tumor types. We are a team of innovative researchers and entrepreneurs with decades of experience building companies and developing computational genomics models. We are dedicated to using today’s data-rich science to personalize medical care. Breakthroughs in biotechnology over recent decades have enabled the comprehensive inventory of gene products in a cancer tumor, amounting to millions of bits of data. These data contain evidence of the genetic lesions that spawned the cancer, and the biological pathways that the tumor may exploit to grow, spread, and eventually take the patient’s life. Identifying these pathways with a diagnostic test is the key to finding the most effective drug for this patient. But discovering and ascertaining this information among the millions of bits of available data is a challenging task. It requires mathematics, computational science, and the ability to translate mathematical models into diagnostic tests that meet the stringent requirements of accuracy and repeatability for clinical use. These are the specialties of Claris GenomiX that allow us to develop multi-gene, mRNA-based diagnostics to help oncologists select the best treatment options for their cancer patients. We use mRNA extracted from tumor tissue for our assays because it is the measurable molecule that best represents how the disease progresses and responds to treatment. Our proprietary mathematical methods can produce mRNA-based diagnostics with clinical-grade accuracy and reliability even with whole-transcriptome (WT) quantification of mRNA.